Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.
Hideaki YamakawaYuko ToyodaTomohisa BabaTomoo KishabaTaiki FukudaTamiko TakemuraKazuyoshi KuwanoPublished in: Journal of clinical medicine (2022)
The presence of a lung lesion is common in microscopic polyangiitis (MPA), and interstitial lung disease (ILD) can lead to a poor prognosis. Although myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) are often present in patients with MPA, patients with ILD and MPO-ANCA positivity but without other manifestations of systemic vasculitis have also been reported. Therefore, the possible association between MPO-ANCA, MPA, and idiopathic ILD remains unclear. This problematic matter has influenced the treatment strategy of MPO-ANCA-positive ILD patients without systemic vasculitis. Clinicians should undertake treatment with careful consideration of the four major causes of death in MPO-ANCA-positive ILD: acute exacerbation of ILD, progressive lung fibrosis, infectious comorbidities, and diffuse alveolar hemorrhage. Further, clinicians need to carefully judge whether inflammation or fibrosis is the dominant condition with reference to the patient's clinical domain and radiopathological lung features. Recently, anti-fibrotic agents such as nintedanib and pirfenidone were shown to be effective in treating various etiologies associated with ILD and have thus led to the widening of treatment options. In this review, the clinical characteristics, radiopathology, prognosis, and therapeutic options in patients with MPO-ANCA-positive ILD are summarized using limited information from previous studies.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- idiopathic pulmonary fibrosis
- rheumatoid arthritis
- poor prognosis
- oxidative stress
- end stage renal disease
- anti inflammatory
- multiple sclerosis
- newly diagnosed
- chronic kidney disease
- liver failure
- respiratory failure
- peritoneal dialysis
- ejection fraction
- replacement therapy